Global NASH/MASH Market Size
The global NASH/MASH Treatment market reached US$ 7.87 billion in 2024 and is expected to reach US$ 31.76 billion by 2033, growing at a CAGR of 17.7% during the forecast period 2025-2033.
NASH (Nonalcoholic Steatohepatitis) and MASH (Metabolic Associated Steatohepatitis) refer to liver conditions characterized by fat accumulation, inflammation, and cellular damage, which can progress to cirrhosis and liver failure. These conditions are increasingly recognized as serious health concerns linked to obesity, insulin resistance, and metabolic syndrome. The treatments aim to reduce liver inflammation, prevent fibrosis progression, and manage associated metabolic disorders, often involving a combination of lifestyle modifications, pharmacotherapy, and emerging targeted therapies.
The NASH/MASH treatment market is rapidly expanding due to the rising prevalence of obesity and metabolic syndromes worldwide. Increasing awareness among healthcare providers and patients, along with substantial investments in research and development, is driving the innovation of new therapeutic agents. Pharmaceutical companies are actively advancing novel drugs through clinical trials, with several promising candidates expected to reach the market soon. Additionally, supportive regulatory frameworks and strategic partnerships are further bolstering market growth, positioning the NASH/MASH treatment market as a critical segment in addressing liver disease and improving patient outcomes globally.
Download Free Sample PDF: https://www.datamintelligence.com/download-sample/nash-or-mash-treatment-market
Market Growth Drivers:
Growing Prevalence of MASLD and NAFLD
The rising rates of Metabolic-Associated Steatotic Liver Disease (MASLD) and Non-Alcoholic Fatty Liver Disease (NAFLD) are expected to drive the growth of the NASH/MASH treatment market. As global incidences of obesity, diabetes, and metabolic syndrome increase, so too does the number of individuals diagnosed with MASLD and NAFLD, creating a larger pool of patients in need of effective therapies. For example, a 2024 report by the National Institute of Health highlighted that over 25% of adults worldwide are affected by MASLD, with more than half of individuals with type 2 diabetes falling into this category. In the United States alone, about 25% of adults have NAFLD, and roughly 20% of these patients progress to NASH. This growing prevalence is set to boost demand for treatments, thereby propelling market growth over the forecast period.
High Costs of NASH/MASH Treatment
However, the substantial costs associated with NASH and MASH treatments pose a significant challenge to market expansion. As these therapies become increasingly specialized, they often require advanced manufacturing processes that drive up production costs. Moreover, since NASH and MASH are chronic conditions, patients typically require long-term care, including ongoing monitoring such as liver function tests, imaging studies, and regular physician consultations. This continuous need for care not only adds to the overall healthcare burden but also increases the financial strain on patients and healthcare systems, potentially slowing down market growth despite the rising prevalence of these conditions.
Market Segments:
By Drug Type: Marketed Drugs, Rezdiffra , Saroglitazar, Emerging DrugsCenicriviroc (CVC) , Elafibranor, Semaglutide , Others
By Distribution Channel: Hospital Pharmacies, Online Pharmacies , Retail Pharmacies
Competitive Landscape
- Ipsen Pharma
- Madrigal Pharmaceuticals
- Zydus Therapeutics Inc.
- Gleason Healthcare
- Novo Nordisk A/S
- Eli Lilly and Company
- 89bio, Inc.
- Boehringer Ingelheim International GmbH
- Akero Therapeutics, Inc.
- NeuroBo Pharmaceuticals, Inc.
Customize Your Scope: https://www.datamintelligence.com/customize/nash-or-mash-treatment-market
Regional Growth
North America: Dominating the NASH/MASH Treatment Market
North America has consistently maintained a significant share of the NASH/MASH treatment medications market, a trend that is expected to continue throughout the forecast period. This sustained leadership is driven by increased FDA approvals and robust research and development efforts in creating innovative MASH treatment drugs. Pharmaceutical companies in the region are heavily investing in R&D to develop new formulations, and many promising pipeline drugs are in various stages of progress. For example, in May 2024, the US-based biopharmaceutical company 89bio initiated the Phase III ENLIGHTEN-Cirrhosis clinical trial to evaluate pegozafermin for treating metabolic dysfunction-associated steatohepatitis (MASH) with compensated cirrhosis, underscoring North America’s market dominance.
Asia-Pacific: Rapid Growth in NASH/MASH Treatments
The Asia-Pacific region is emerging as the fastest-growing market for NASH/MASH treatments. This rapid expansion is largely driven by the rising incidence of obesity and metabolic syndrome in key countries such as India, China, and Japan, which are major contributors to the prevalence of NASH and MASH. Alongside these health trends, significant advancements in research and the development of new drug formulations are accelerating the region’s growth in this market.
A Dual-Regional Outlook
While North America continues to lead with its strong infrastructure, advanced R&D, and regulatory support, Asia-Pacific is catching up quickly due to its burgeoning patient base and innovative pharmaceutical developments. Both regions play a critical role in shaping the global landscape for NASH/MASH treatments, ensuring that new therapeutic options continue to emerge and meet the growing global demand for effective liver disease management.
Key Development:
In October 2024, Boehringer Ingelheim announced that the FDA granted Breakthrough Therapy designation for survodutide (BI 456906), a dual glucagon/GLP-1 receptor agonist developed for treating adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) accompanied by moderate or advanced fibrosis (stages 2 or 3).
For Detailed Report: https://www.datamintelligence.com/enquiry/nash-or-mash-treatment-market
